The Advanced Breast Cancer (ABC) 8th international consensus conference took place on 6-8 November 2025, in Lisbon, and updated the previous ABC international consensus guidelines that are described in this manuscript. These guidelines reflect the work of a large and global consensus panel, comprising healthcare profes...
F. Cardoso, J. Ribeiro, E. Schumacher-Wulf et al.· Breast· 0 citations
BACKGROUND AND PURPOSE
The treatment landscape for breast cancer has undergone significant advancements in the recent years, with the introduction of several new anticancer agents, especially those belonging to the antibody-drug conjugates (ADCs) class. However, there exists a lack of comprehensive evidence regarding t...
L. Visani, C. Becherini, M. Kubeczko et al.· Radiotherapy and Oncology· 0 citations
BACKGROUND
The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2...
J. Garber, D. Cameron, C. Campbell et al.· Annals of Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.